Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Classical hematology 2

Conditions

Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Anemia, Refractory, with Excess of Blasts 2Pancreatic Neoplasms 1Cytopenia 1

Interventions

Cytarabine 9Daunorubicin 7Etoposide 6Methotrexate 5Idarubicin 5Thioguanine 4Mitoxantrone 4Cyclophosphamide 4Hydrocortisone 3Granulocyte Colony-Stimulating Factor 3Filgrastim 3Asparaginase 3Tacrolimus 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2ON 01910 2Mycophenolic Acid 2Dexamethasone 2Busulfan 2zosuquidar trihydrochloride 1valspodar 1tipifarnib 1sargramostim 1palmitoyl-L-asparaginase 1merphos 1lonafarnib 1hydrocortisone hemisuccinate 1fludarabine phosphate 1fludarabine 1cc-486 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Anemia, Refractory, with Excess of Blasts × ON 01910 × Clear all
NCT01241500 2020-06-30

ONTIME

Traws Pharma, Inc.

Phase 3 Completed
299 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT01928537 2020-06-30

Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine

Traws Pharma, Inc.

Phase 3 Completed
67 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Cytopenia, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡